

REFERENCES USED IN ALGORITHMS FOR THE TREATMENT OF PERSONS WITH RHEUMATOID ARTHRITIS

1. Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, Deane KD, Genovese M, Huston KK, Kerr G *et al*: **2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis**. *Arthritis Care Res (Hoboken)* 2021, **73**(7):924-939.
2. Singh J, Saag K, Bridges Jr. S, Akl E, Raveendhara R, Bannuru MCS, Elizaveta Vaysbrot,, Christine mcnaughton mo, robert h. Shmerling, jeffrey r. Curtis,, Daniel e. Furst dp, arthur kavanaugh, james o'dell, charles king,, Amye leong elM, john t. Schousboe, barbara drevlow,, Seth ginsberg jg, e. William st.clair, elizabeth tindall,, Amy s. Miller tm: **2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis**. *Arthritis Care & Research* 2015.
3. Bombardier C, Hazlewood GS, Akhavan P, Schieir O, Dooley A, Haraoui B, Khraishi M, Leclercq SA, Legare J, Mosher DP *et al*: **Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety**. *The Journal of rheumatology* 2012, **39**(8):1583-1602.
4. European League Against Rheumatism: **EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update**. In: *Annals of the rheumatic diseases*. 2016.
5. National Institute for Health and Care Excellence: **Drug treatment for rheumatoid arthritis**. In.; 2018.
6. Hazlewood G, Bykerk VP: **Rheumatoid Arthritis**. In: *Therapeutics*. Edited by Jovaisas B. Ottawa (ON): Canadian Pharmacists Association; 2015.
7. Capell HA, Madhok R, Porter DR, Munro RA, McInnes IB, Hunter JA, Steven M, Zoma A, Morrison E, Sambrook M *et al*: **Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study**. *Ann Rheum Dis* 2007, **66**(2):235-241.
8. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, Luggen ME, Keystone E, Weisman MH, Bensen WM *et al*: **Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial**. *Ann Intern Med* 2002, **137**(9):726-733.
9. Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M, Meusser S, Paimela L, Rau R, Zeidler H *et al*: **Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components**. *Ann Rheum Dis* 1999, **58**(4):220-225.
10. Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB: **Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial**. *British journal of rheumatology* 1997, **36**(10):1082-1088.
11. Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, Bridges SL, Jr., Zhang J, McVie T, Howard G *et al*: **A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial**. *Arthritis Rheum* 2012, **64**(9):2824-2835.

12. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, Laasonen L, Julkunen H, Luukkainen R, Vuori K *et al*: **Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.** *Lancet* 1999, **353**(9164):1568-1573.
13. de Jong PH, Hazes JM, Barendregt PJ, Huisman M, van Zeven D, van der Lubbe PA, Gerards AH, de Jager MH, de Sonnaville PB, Grillet BA *et al*: **Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial.** *Ann Rheum Dis* 2013, **72**(1):72-78.
14. Saunders SA, Capell HA, Stirling A, Vallance R, Kincaid W, McMahon AD, Porter DR: **Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.** *Arthritis Rheum* 2008, **58**(5):1310-1317.
15. Rheumatism TELA: **EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update** In.; 2020.
16. Donahue KE SE, Gartlehner G, Jonas BL, Coker-Schwimmer E, Patel SV4, Weber RP, Bann CM, Viswanathan M.: **Comparative Effectiveness of Combining MTX with Biologic Drug Therapy Versus Either MTX or Biologics Alone for Early Rheumatoid Arthritis in Adults: a Systematic Review and Network Meta-analysis.** In: *J Gen Intern Med.* 2019.
17. Katchamart W, Trudeau J, Phumethum V, Bombardier C: **Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis.** *The Cochrane database of systematic reviews* 2010(4):CD008495.
18. Shea B, Swinden MV, Tanjong Ghogomu E, Ortiz Z, Katchamart W, Rader T, Bombardier C, Wells GA, Tugwell P: **Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.** *The Cochrane database of systematic reviews* 2013, **5**:CD000951.
19. Canadian Agency for Drugs and Technologies in Health: **Biologic Switching for Patients with Rheumatoid Arthritis: A Review of Clinical Effectiveness, Safety, and Guidelines.** In.; 2015.
20. Iannaccone CK, Lee YC, Cui J, Frits ML, Glass RJ, Plenge RM, Solomon DH, Weinblatt ME, Shadick NA: **Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study.** *Rheumatology (Oxford, England)* 2011, **50**(1):40-46.
21. Lee YC, Cui J, Costenbader KH, Shadick NA, Weinblatt ME, Karlson EW: **Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate.** *Rheumatology (Oxford, England)* 2009, **48**(6):613-617.
22. Lacruz-Guzman D, Torres-Moreno D, Pedrero F, Romero-Cara P, Garcia-Tercero I, Trujillo-Santos J, Conesa-Zamora P: **Influence of polymorphisms and TNF and IL1beta serum concentration on the infliximab response in Crohn's disease and ulcerative colitis.** *Eur J Clin Pharmacol* 2013, **69**(3):431-438.
23. Tong Q, Zhao L, Qian XD, Zhang LL, Xu X, Dai SM, Cai Q, Zhao DB: **Association of TNF-alpha polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis.** *Pharmacogenomics* 2013, **14**(14):1691-1700.

24. Song GG, Seo YH, Kim JH, Choi SJ, Ji JD, Lee YH: **Association between TNF-alpha (-308 A/G, -238 A/G, -857 C/T) polymorphisms and responsiveness to TNF-alpha blockers in spondyloarthritis, psoriasis and Crohn's disease: a meta-analysis.** *Pharmacogenomics* 2015, **16**(12):1427-1437.
25. Netz U, Carter JV, Eichenberger MR, Dryden GW, Pan J, Rai SN, Galandiuk S: **Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease.** *World J Gastroenterol* 2017, **23**(27):4958-4967.
26. Tavares M, de Lima C, Fernandes W, Martinelli V, de Lucena M, Lima F, Telles A, Brandao L, de Melo Junior M: **Tumour necrosis factor-alpha (-308G/A) promoter polymorphism is associated with ulcerative colitis in Brazilian patients.** *Int J Immunogenet* 2016, **43**(6):376-382.
27. Zeng Z, Duan Z, Zhang T, Wang S, Li G, Gao J, Ye D, Xu S, Xu J, Zhang L *et al*: **Association between tumor necrosis factor-alpha (TNF-alpha) promoter -308 G/A and response to TNF-alpha blockers in rheumatoid arthritis: a meta-analysis.** *Modern rheumatology / the Japan Rheumatism Association* 2013, **23**(3):489-495.
28. Daien CI, Fabre S, Rittore C, Soler S, Daien V, Tejedor G, Cadart D, Molinari N, Daures JP, Jorgensen C *et al*: **TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis.** *Joint Bone Spine* 2012, **79**(5):471-475.
29. Maxwell JR, Potter C, Hyrich KL, Barton A, Worthington J, Isaacs JD, Morgan AW, Wilson AG: **Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis.** *Hum Mol Genet* 2008, **17**(22):3532-3538.
30. Marotte H, Arnaud B, Diasparra J, Zrioual S, Miossec P: **Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor.** *Arthritis Rheum* 2008, **58**(5):1258-1263.
31. Miceli-Richard C, Comets E, Verstuyft C, Tamouza R, Loiseau P, Ravaud P, Kupper H, Becquemont L, Charron D, Mariette X: **A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis.** *Ann Rheum Dis* 2008, **67**(4):478-484.
32. Guis S, Balandraud N, Bouvenot J, Auger I, Toussirot E, Wendling D, Mattei JP, Nogueira L, Mugnier B, Legeron P *et al*: **Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis.** *Arthritis Rheum* 2007, **57**(8):1426-1430.
33. Seitz M, Wirthmuller U, Moller B, Villiger PM: **The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.** *Rheumatology (Oxford)* 2007, **46**(1):93-96.
34. Cuchacovich M, Soto L, Edwardes M, Gutierrez M, Llanos C, Pacheco D, Sabugo F, Alamo M, Fuentealba C, Villanueva L *et al*: **Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis.** *Scand J Rheumatol* 2006, **35**(6):435-440.
35. Fonseca JE, Carvalho T, Cruz M, Nero P, Sobral M, Mourao AF, Cavaleiro J, Ligeiro D, Abreu I, Carmo-Fonseca M *et al*: **Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics.** *Ann Rheum Dis* 2005, **64**(5):793-794.

36. Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D: **Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis.** *Arthritis Rheum* 2003, **48**(7):1849-1852.
37. Padyukov L, Lampa J, Heimbürger M, Ernestam S, Cederholm T, Lundkvist I, Andersson P, Hermansson Y, Harju A, Klareskog L *et al*: **Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis.** *Ann Rheum Dis* 2003, **62**(6):526-529.
38. Nishio M, Endo T, Fujimoto K, Yamamoto S, Obara M, Yamaguchi K, Takeda Y, Goto H, Kasahara I, Sato N *et al*: **FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation.** *Eur J Haematol* 2009, **82**(2):143-147.
39. Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, Do YR, Shin HJ, Kim MK, Hyun MS *et al*: **FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.** *Blood* 2006, **108**(8):2720-2725.
40. Weng WK, Levy R: **Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.** *J Clin Oncol* 2003, **21**(21):3940-3947.
41. Pfizer Canada ULC: **Methotrexate.** In: *CA Product monograph.* Kirkland QC; 2019.
42. Medexus Inc: **Metosject Subcutaneous (methotrexate).** In: *CA Product Monograph.* Bolton, ON; 2019.
43. Accord Healthcare Inc: **ACH-Methotrexate.** In: *CA Product Monograph.* Kirkland QC; 2022.
44. Accord Healthcare Inc: **Methotrexate.** In: *US Product Monograph.* Durham, NC; 2021.
45. Antares Pharma Inc: **Otrexup (methotrexate).** In: *US Product Monograph.* Ewing, NJ; 2019.
46. Medexus Pharma Inc: **Rasuvo (methotrexate).** In: *US Product Monograph.* Chicago, IL; 2020.
47. Alvogen Inc: **Methotrexate.** In: *US Product Monograph.* Morristown, NJ; 2022.
48. Sanis Health Inc: **Hydroxychloroquine.** In: *CA Product Monograph.* Brampton, ON; 2022.
49. Jubilant Cadista Pharmaceuticals Inc: **Hydroxychloroquine.** In: *US Product Monograph.* Salisbury, MD; 2022.
50. Accel Pharma Inc: **Leflunomide.** In: *Health Canada Product Monograph.* 2018.
51. Winthrop US: **Leflunomide.** In: *US Product Monograph.* Bridgewater, NJ; 2022.
52. Pharmascience Inc: **pms-SULFASALAZINE.** In: *CA Product Monograph.* Montreal, QC; 2020.
53. Pfizer Laboratories Div Pfizer Inc: **Azulfidine (sulfasalazine).** In: *US Product Monograph.* New York, NY; 2021.
54. AbbVie Corporation: **Humira (adalimumab).** In: *CA Product Monograph.* St-Laurent, QC; 2021.

55. AbbVie Inc: **Humira (adalimumab)**. In: *US Product Monograph*. North Chicago, IL; 2021.
56. Pfizer Canada ULC: **Abrilada (adalimumab)**. In: *CA Product Monograph*. Kirkland, QC; 2021.
57. Amgen Canada Inc: **Amgevita**. In: *CA Product Monograph*. Mississauga, ON; 2021.
58. Organon Canada Inc: **Hadlima (adalimumab biosimilar)**. In: *CA Product Monograph*. Kirkland, QC; 2021.
59. BGP Pharma ULC: **Hulio (Adalimumab injection)**. In: *CA Product Monograph*. Etobicoke, ON; 2022.
60. Sandoz Canada Inc: **Hyrimoz (Adalimumab Injection)**. In: *CA Product Monograph*. Boucherville, QC; 2021.
61. Fresenius Kabi Canada Ltd: **Indacio (adalimumab)**. In: *CA Product Monograph*. Toronto, ON; 2020.
62. Jamp Pharma Corporation: **Simlandi (adalimumab)**. In: *CA Product Monograph*. Boucherville, QC; 2022.
63. Celltrion Healthcare Canada Limited: **Yuflyma (adalimumab)**. In: *CA Product Monograph*. South Waterloo, ON; 2021.
64. Pfizer Inc: **Abrilada (adalimumab-afzb)**. In: *US Product Monograph*. New York, NY; 2022.
65. Amgen Inc: **Amjevita (adalimumab-atto)**. In: *US Product Monograph*. Thousand Oaks, CA; 2022.
66. Boehringer Ingelheim Pharmaceuticals Inc: **Cyltezo (adalimumab-adbm)**. In: *US Product Monograph*. Ridgefield, CT; 2021.
67. Organon & Co: **Hadlima (adalimumab-bwwd)**. In: *US Product Monograph*. Jersey City, NJ; 2022.
68. Mylan Pharmaceuticals Inc: **Hulio (adalimumab-fkjp)**. In: *US Product Monograph*. Morgantown, West Virginia; 2022.
69. Sandoz Inc: **Hyrimoz (adalimumab-adaz)**. In: *US Product Monograph*. Princeton, NJ; 2022.
70. Coherus BioSciences: **Yusimry (adalimumab-aqvh)**. In: *US Product Monograph*. Redwood City, CA; 2021.
71. UCB Canada Inc: **Cimzia (certolizumab)**. In: *CA Product Monograph*. Oakville, ON; 2019.
72. UCB Inc: **Cimzia (certolizumab)**. In: *US Product Monograph*. Smyrna, GA; 2021.
73. Amgen Canada inc: **Enbrel (etanercept)**. In: *CA Product Monograph*. Mississauga, ON; 2021.
74. Immunex Corporation: **Enbrel (etanercept)**. In: *US Product Monograph*. Thousands Oaks, CA; 2022.
75. Amgen: **Enbrel (etanercept)**. In: *Health Canada Product Monograph*. Mississauga, ON; 2019.
76. Immunex: **Enbrel (etanercept)**. In: *FDA Product Monograph*. Thousand Oaks, CA; 2019.
77. Samsung Bioepis: **Brenzys (etanercept)**. In: *CA Product Monograph*. Yeonsu-gu, Incheon, Republic of Korea; 2022.

78. Sandoz Canada Inc.: **Erelzi (etanercept)**. In: *CA Product Monograph*. Boucherville, QC; 2021.
79. Sandoz Inc.: **Erelzi (etanercept-szzs)**. In: *US Product Monograph*. Princeton, NJ; 2020.
80. Samsung Bioepis: **Eticovo (etanercept)**. In: *US Product Monograph*. Incheon, Korea; 2019.
81. Samsung Bioepis: **Brenzys (etanercept)**. In: *CA Product Monograph*. Incheon, Korea; 2018.
82. Sandoz: **Erelzi (etanercept)**. In: *CA Product Monograph*. Boucherville, Québec; 2019.
83. Sandoz: **Erelzi (etanercept)**. In: *US Product Monograph*. Princeton, NJ; 2019.
84. Janssen Inc.: **Simponi, Simponi IV (golimumab)**. In: *CA Product Monograph*. Toronto, ON; 2022.
85. Janssen Biotech Inc.: **Simponi Aria (golimumab)**. In: *US Product Monograph*. Horsham, PA; 2021.
86. Biotech J: **Simponi (golimumab)**. In: *US Product Monograph*. Horsham, PA; 2019.
87. Janssen: **Simponi (golimumab)**. In: *CA Product Monograph*. Toronto, ON; 2019.
88. Janssen Biotech Inc: **Simponi Aria (golimumab)**. In: *US Product Monograph*. Horsham, PA; 2019.
89. Bristol-Myers Squibb Canada: **Orencia (abatacept)**. In: *CA Product Monograph*. Montreal, QC; 2022.
90. ER Squibb & Sons LLC: **Orencia (abatacept)**. In: *US Product Monograph*. Princeton, NJ; 2021.
91. Bristol Myers Squibb: **Abatacept**. In: *Health Canada Product Monograph*. Montreal Canada; 2019.
92. ER Squibb & Son **Abatacept**. In: *FDA Product Monograph*. 2019.
93. Sanofi Aventis: **Kevzara (sarilumab)**. In: *CA Product Monograph*. Mississauga, ON; 2019.
94. Sanofi-aventis US LLC: **Kevzara (sarilumab)**. In: *US Product Monograph*. Bridgewater, NJ; 2018.
95. Sanofi Aventis: **Kevzara (sarilumab)**. In: *US Product Monograph*. Bridgewater, NJ; 2019.
96. Hoffmann-La Roche Limited: **Actemra (tocilizumab)**. In: *CA Product Monograph*. Mississauga, ON; 2021.
97. Genentech Inc.: **Actemra (tocilizumab)**. In: *US Product Monograph*. San Francisco, CA; 2022.
98. Hoffmann-La Roche: **Actemra (tocilizumab)**. In: *CA Product Monograph*. Mississauga, Ontario, Canada; 2019.
99. Genentech: **Actemra (tocilizumab)**. In: *US Product Monograph*. South San Francisco, CA; 2019.
100. Hoffman-La Roche Ltd: **Rituxan (rituximab)**. In: *CA Product Monograph*. Mississauga, Ontario; 2019.
101. Genentech Inc.: **Rituxan (rituximab)**. In: *US Product Monograph*. San Francisco, CA; 2021.

102. Genentech: **Rituxan (rituximab)**. In: *US Product Monograph*. South San Francisco, CA; 2020.
103. Amgen Canada Inc.: **Riabni (rituximab)**. In: *CA Product Monograph*. Mississauga, ON; 2021.
104. Sandoz Canada Inc.: **Riximyo (rituximab)**. In: *CA Product Monograph*. Boucherville, QC; 2022.
105. Pfizer Canada ULC: **Ruxience (rituximab)**. In: *CA Product Monograph*. Kirkland, QC; 2020.
106. Teva Canada Limited: **Truxima (rituximab)**. In: *CA Product Monograph*. Toronto, ON; 2020.
107. Amgen Inc.: **Riabni (rituximab-arrr)**. In: *US Product Monograph*. Thousand Oaks, CA; 2022.
108. Pfizer Laboratories Div Pfizer Inc: **Ruxience (rituximab-pvvr)**. In: *US Product Monograph*. New York, NY; 2021.
109. Cephalon Inc.: **Truxima (rituximab-abbs)**. In: *US Product Monograph*. North Wales, PA; 2021.
110. Teva Canada Limited: **Truxima (rituximab)**. In: *CA Product Monograph*. Toronto, Ontario; 2019.
111. Pfizer: **Ruxience (rituximab)**. In: *US Product Monograph*. NY, NY; 2019.
112. Celltrion: **Truxima (rituximab)**. In: *US Product Monograph*. 2019.
113. Eli Lilly Canada Inc.: **Olumiant (baricitinib)**. In: *CA Product Monograph*. Toronto, ON; 2022.
114. Eli Lilly and Company: **Olumiant (baricitinib)**. In: *US Product Monograph*. Indianapolis, IN; 2022.
115. Eli Lilly Canada: **Baricitinib**. In: *Health Canada Product Monograph*. 2018.
116. Eli Lilly and Company: **Baricitinib**. In: *FDA Product Monograph*. 2019.
117. Pfizer Canada ULC: **Xeljanz, Xeljanz XR (tofacitinib)**. In: *CA Product Monograph*. Kirkland, QC; 2022.
118. Pfizer Laboratories Div Pfizer Inc: **Xeljanz, Xeljanz XR (tofacitinib)**. In: *US Product Monograph*. New York, NY; 2022.
119. Pfizer Canada: **Xeljanz (tofacitinib)**. In: *Health Canada Product Monograph*. 2019.
120. Pfizer: **Xeljanz (tofacitinib)**. In: *US Product Monograph*. 2019.
121. AbbVie Corporation: **Rinvoq (upadacitinib)**. In: *CA Product Monograph*. St-Laurent, QC; 2022.
122. AbbVie Inc.: **Rinvoq (upadacitinib)**. In: *US Product Monograph*. North Chicago, IL; 2022.
123. AbbVie: **Upadacitinib**. In: *Health Canada Product Monograph*. 2019.
124. AbbVie: **Upadacitinib**. In: *FDA Product Monograph*. 2020.